• Trial met all Phase 3 endpoints and regimen is well-tolerated with all patients completing 48 weeks of treatment
• 100% of patients achieved virologic response at Week 24 with 79% of patients reaching undetectable virus (as defined by HDV RNA TND) at Week 48
• Comprehensive regulatory filing package planned for U.S. FDA submission mid-2027

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.